Form 4: BridgeBio Pharma CEO Sells Shares
Insider Transaction (Form 4)
Neil Kumar, Chief Executive Officer and a Director of BridgeBio Pharma, Inc., sold 10,000 shares of common stock on September 17, 2026.
Summary
- Open-market sale: disposed of 8,721 Common Stock at $69.01 ($601,868) on September 17, 2026; holds 496,965 after (Indirect).
- Open-market sale: disposed of 1,279 Common Stock at $69.57 ($88,980) on September 17, 2026; holds 495,686 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $690,847 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Neil Kumar — Director, Officer (Chief Executive Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-17 | Open-market sale | Common Stock | 8,721 | $69 | $601.9K | 496,965 |
| 2026-09-17 | Open-market sale | Common Stock | 1,279 | $70 | $89.0K | 495,686 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-17 | Open-market sale (8,721 shares) |
| 2026-09-17 | Open-market sale (1,279 shares) |
Keywords
insider transaction, Form 4, BBIO, BridgeBio Pharma, Inc., bearish, Neil Kumar
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.